| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Fanlian Huazhuo Formula alleviates high-fat diet-induced non-alcoholic fatty liver disease by modulating autophagy and lipid synthesis signaling pathway
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Meng-Yuan Niu, Geng-Ting Dong, Yi Li, Qing Luo, Liu Cao, Xi-Min Wang, Qi-Wen Wang, Yi-Ting Wang, Zhe Zhang, Xi-Wen Zhong, Wei-Bo Dai and Le-Yu Li |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Basic and Applied Basic Research Found of Guangdong Province |
2022A1515011307 |
|
| Corresponding Author |
Le-Yu Li, MS, Chief Physician, Department of Endocrinology, Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, No. 3 Kangxin Road, West District, Zhongshan 528400, Guangdong Province, China. lileyu@zsszyy.net |
| Key Words |
Fanlian Huazhuo Formula; Nonalcoholic fatty liver disease; Autophagy; apoptosis; AMPKα/SREBP-1C signal pathway; Oxidative stress |
| Core Tip |
Fanlian Huazhuo Formula (FLHZF) has traditionally been used for treating type 2 diabetes mellitus. It has shown significant potential in treating non-alcoholic fatty liver disease (NAFLD) based on experimental research conducted in vivo and in vitro. Studies suggest that FLHZF may improve NAFLD by reducing oxidative stress, activating cellular autophagy, and regulating lipid metabolism signaling pathways. These findings provide new insights into the mechanism of action of FLHZF, and offer a theoretical basis for its application in the clinical treatment of NAFLD, potentially expanding its scope of use. |
| Publish Date |
2024-08-09 12:51 |
| Citation |
<p>Niu MY, Dong GT, Li Y, Luo Q, Cao L, Wang XM, Wang QW, Wang YT, Zhang Z, Zhong XW, Dai WB, Li LY. Fanlian Huazhuo Formula alleviates high-fat diet-induced non-alcoholic fatty liver disease by modulating autophagy and lipid synthesis signaling pathway. <i>World J Gastroenterol</i> 2024; 30(30): 3584-3608</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i30/3584.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i30.3584 |
